BR9911648A - Composição farmacêutica de liberação controlada e processo de liberação de agente farmaceuticamente ativo - Google Patents
Composição farmacêutica de liberação controlada e processo de liberação de agente farmaceuticamente ativoInfo
- Publication number
- BR9911648A BR9911648A BR9911648-0A BR9911648A BR9911648A BR 9911648 A BR9911648 A BR 9911648A BR 9911648 A BR9911648 A BR 9911648A BR 9911648 A BR9911648 A BR 9911648A
- Authority
- BR
- Brazil
- Prior art keywords
- active agent
- pharmaceutically active
- molecular weight
- average molecular
- controlled release
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Patente de Invenção: para <B>"COMPOSIçãO FARMACêUTICA DE LIBERAçãO CONTROLADA E PROCESSO DE LIBERAçãO DE AGENTE FARMACEUTICAMENTE ATIVO"<D>. A presente invenção refere-se a composições farmacêuticas sólidas para forma de dosagem oral, de liberação controlada que contêm quantidades terapêuticas de um agente farmaceuticamente ativo, hidroxipropil metil celulose e um polímero hidrofílico não-iónico selecionado do grupo que consiste em hidroxietil celulose que tem um peso molecular médio em número na faixa de desde 90.000 até 1.300.000, hidroxipropil celulose que tem um peso molecular médio em número de 370.000 até 1.500.000 e poli(óxido de etileno) que tem um peso molecular médio em número na faixa de desde 100.000 até 500.000.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17249198A | 1998-10-14 | 1998-10-14 | |
PCT/EP1999/007627 WO2000021525A2 (en) | 1998-10-14 | 1999-10-12 | Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9911648A true BR9911648A (pt) | 2001-03-20 |
Family
ID=22627919
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9911648-0A BR9911648A (pt) | 1998-10-14 | 1999-10-12 | Composição farmacêutica de liberação controlada e processo de liberação de agente farmaceuticamente ativo |
Country Status (30)
Country | Link |
---|---|
EP (1) | EP1121116B1 (pt) |
JP (2) | JP2002527388A (pt) |
KR (1) | KR100517090B1 (pt) |
CN (1) | CN1196481C (pt) |
AR (2) | AR020780A1 (pt) |
AT (1) | ATE382345T1 (pt) |
AU (1) | AU765475B2 (pt) |
BR (1) | BR9911648A (pt) |
CA (1) | CA2346868C (pt) |
CO (1) | CO5140079A1 (pt) |
CY (1) | CY1107874T1 (pt) |
DE (1) | DE69937891T2 (pt) |
DK (1) | DK1121116T3 (pt) |
ES (1) | ES2297936T3 (pt) |
HK (1) | HK1040920B (pt) |
HU (1) | HUP0104268A3 (pt) |
ID (1) | ID29350A (pt) |
IL (2) | IL142375A0 (pt) |
MY (1) | MY121105A (pt) |
NO (1) | NO327285B1 (pt) |
NZ (1) | NZ511010A (pt) |
PE (1) | PE20001110A1 (pt) |
PL (1) | PL198850B1 (pt) |
PT (1) | PT1121116E (pt) |
RU (1) | RU2259826C2 (pt) |
SK (2) | SK286596B6 (pt) |
TR (1) | TR200101088T2 (pt) |
TW (1) | TW577738B (pt) |
WO (1) | WO2000021525A2 (pt) |
ZA (1) | ZA200103001B (pt) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6569461B1 (en) | 1999-03-08 | 2003-05-27 | Merck & Co., Inc. | Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors |
US6242003B1 (en) * | 2000-04-13 | 2001-06-05 | Novartis Ag | Organic compounds |
CZ20024015A3 (cs) | 2000-06-09 | 2003-04-16 | Lek Pharmaceutical D.D. | Stabilní farmaceutický produkt a jeho formulace |
KR100833469B1 (ko) * | 2000-09-29 | 2008-05-29 | 솔베이 파마슈티칼스 비. 브이 | 이온 농도에 비의존적인 지속 방출성 약제학적 제형 |
US20060127474A1 (en) | 2001-04-11 | 2006-06-15 | Oskar Kalb | Pharmaceutical compositions comprising fluvastatin |
WO2004024184A1 (ja) * | 2002-09-11 | 2004-03-25 | Takeda Pharmaceutical Company Limited | 徐放性製剤 |
JP2007523664A (ja) | 2003-04-23 | 2007-08-23 | フェリング ベスローテン フェンノートシャップ | 医薬組成物用サシェ |
US8987322B2 (en) | 2003-11-04 | 2015-03-24 | Circ Pharma Research And Development Limited | Pharmaceutical formulations for carrier-mediated transport statins and uses thereof |
DE102004062475A1 (de) * | 2004-12-24 | 2006-07-06 | Bayer Healthcare Ag | Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung |
KR100582347B1 (ko) * | 2004-12-30 | 2006-05-22 | 한미약품 주식회사 | 3-하이드록시-3-메틸글루타릴 조효소 a 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법 |
CA2615941A1 (en) * | 2005-08-05 | 2007-02-15 | Orbus Pharma Inc. | Stabilized extended release pharmeceutical compositions comprising an hmg-coa reductase inhibitor |
EP1825847A3 (en) * | 2006-02-24 | 2008-01-23 | Teva Pharmaceutical Industries Ltd | Fluvastatin sodium pharmaceutical compositions |
RU2356532C2 (ru) * | 2007-06-01 | 2009-05-27 | Открытое Акционерное Общество "Отечественные Лекарства" | Фармацевтическая композиция проксодолола с контролируемым высвобождением |
CN102805739B (zh) * | 2012-04-10 | 2013-08-14 | 宋芸 | 氟伐他汀钠缓释包衣滴丸及其制备方法 |
AU2014205356A1 (en) * | 2013-01-09 | 2015-07-30 | Edgemont Pharmaceuticals Llc | Controlled release formulations of lorazepam |
CN106344535B (zh) * | 2016-08-29 | 2019-09-20 | 济南康和医药科技有限公司 | 一种氟伐他汀钠微孔渗透泵控释片及其制备方法 |
AU2018379992B2 (en) | 2017-12-05 | 2022-07-21 | Sunovion Pharmaceuticals Inc. | Nonracemic mixtures and uses thereof |
CN112236138B (zh) | 2017-12-05 | 2024-05-31 | 赛诺维信制药公司 | 晶体形式及其制备方法 |
BR112021005668A2 (pt) | 2018-09-25 | 2021-06-22 | Ponce De Leon Health Designated Activity Company | processo para fabricação de alfa-cetoglutarato de cálcio |
CN114401717A (zh) | 2019-06-04 | 2022-04-26 | 赛诺维信制药公司 | 修饰释放配制品及其用途 |
EP3980001A4 (en) * | 2019-06-10 | 2023-06-21 | Ponce de Leon Health Designated Activity Company | COMPOSITIONS OF ALPHA-KETOGLUTARATE DELAYED RELEASE |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4915954A (en) * | 1987-09-03 | 1990-04-10 | Alza Corporation | Dosage form for delivering a drug at two different rates |
CA2045428A1 (en) * | 1990-06-26 | 1991-12-27 | Alfred W. Alberts | Method for enhancing the lowering of plasma cholesterol levels |
GB9523752D0 (en) * | 1995-11-21 | 1996-01-24 | Pfizer Ltd | Pharmaceutical formulations |
RU2142790C1 (ru) * | 1995-12-22 | 1999-12-20 | Кова Компани Лтд | Фармацевтическая композиция, стабилизированная основным агентом |
SE9603667D0 (sv) * | 1996-10-08 | 1996-10-08 | Astra Ab | Pharmaceutical compositions |
-
1999
- 1999-10-05 CO CO99062951A patent/CO5140079A1/es unknown
- 1999-10-12 CN CNB998120812A patent/CN1196481C/zh not_active Expired - Lifetime
- 1999-10-12 SK SK5054-2008A patent/SK286596B6/sk not_active IP Right Cessation
- 1999-10-12 ID IDW20010807A patent/ID29350A/id unknown
- 1999-10-12 RU RU2001111882/15A patent/RU2259826C2/ru active
- 1999-10-12 IL IL14237599A patent/IL142375A0/xx unknown
- 1999-10-12 JP JP2000575501A patent/JP2002527388A/ja active Pending
- 1999-10-12 PL PL348109A patent/PL198850B1/pl unknown
- 1999-10-12 NZ NZ511010A patent/NZ511010A/en not_active IP Right Cessation
- 1999-10-12 EP EP99947489A patent/EP1121116B1/en not_active Revoked
- 1999-10-12 PT PT99947489T patent/PT1121116E/pt unknown
- 1999-10-12 AU AU60909/99A patent/AU765475B2/en not_active Expired
- 1999-10-12 WO PCT/EP1999/007627 patent/WO2000021525A2/en active Application Filing
- 1999-10-12 DE DE69937891T patent/DE69937891T2/de not_active Expired - Lifetime
- 1999-10-12 AR ARP990105146A patent/AR020780A1/es not_active Application Discontinuation
- 1999-10-12 DK DK99947489T patent/DK1121116T3/da active
- 1999-10-12 PE PE1999001027A patent/PE20001110A1/es not_active IP Right Cessation
- 1999-10-12 SK SK509-2001A patent/SK286595B6/sk not_active IP Right Cessation
- 1999-10-12 TR TR2001/01088T patent/TR200101088T2/xx unknown
- 1999-10-12 KR KR10-2001-7004708A patent/KR100517090B1/ko active IP Right Grant
- 1999-10-12 BR BR9911648-0A patent/BR9911648A/pt not_active Application Discontinuation
- 1999-10-12 AT AT99947489T patent/ATE382345T1/de active
- 1999-10-12 HU HU0104268A patent/HUP0104268A3/hu not_active Application Discontinuation
- 1999-10-12 CA CA002346868A patent/CA2346868C/en not_active Expired - Lifetime
- 1999-10-12 ES ES99947489T patent/ES2297936T3/es not_active Expired - Lifetime
- 1999-10-13 MY MYPI99004430A patent/MY121105A/en unknown
- 1999-10-14 TW TW088117692A patent/TW577738B/zh not_active IP Right Cessation
-
2001
- 2001-04-02 IL IL142375A patent/IL142375A/en not_active IP Right Cessation
- 2001-04-04 NO NO20011695A patent/NO327285B1/no not_active IP Right Cessation
- 2001-04-11 ZA ZA200103001A patent/ZA200103001B/en unknown
-
2002
- 2002-04-10 HK HK02102698.9A patent/HK1040920B/zh not_active IP Right Cessation
-
2006
- 2006-08-14 JP JP2006221194A patent/JP4938383B2/ja not_active Expired - Fee Related
-
2008
- 2008-02-04 CY CY20081100134T patent/CY1107874T1/el unknown
- 2008-11-11 AR ARP080104921A patent/AR069281A2/es not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9911648A (pt) | Composição farmacêutica de liberação controlada e processo de liberação de agente farmaceuticamente ativo | |
RU2004137118A (ru) | Фармацевтическая композиция для контролируемого высвобождения активных веществ и способ ее изготовления | |
Owen et al. | An in vitro study of plasticized poly (lactic‐co‐glycolic acid) films as possible guided tissue regeneration membranes: material properties and drug release kinetics | |
IE970588A1 (en) | Controlled release pharmaceutical compositions containing tiagabine | |
BR0007360A (pt) | Composição de liberação controlada | |
BRPI0512177A (pt) | formulação de liberação modificada de memantina | |
RS20070511A (en) | Modified release pharmaceutical compositions and processes thereof | |
BR0111016A (pt) | Composições farmacêuticas de liberação sustentada para a administração parenteral de compostos hidrófilos biologicamente ativos | |
BR9901782A (pt) | Forma para dosagem de nefazodona. | |
WO2004108162A3 (en) | Controlled release pharmaceutical composition | |
BR112013022057B1 (pt) | Solução oftálmica para tratamento de conjuntivite ocular alérgica | |
KR101066763B1 (ko) | 온도 반응성 전달계 | |
UY25443A1 (es) | Procedimiento para la preparacion de principio activo peroral | |
ATE375789T1 (de) | Orales abgabesystem mit einem antibakteriellen und einem entzündungshemmenden mittel | |
JP2002527388A5 (pt) | ||
JP2003206241A (ja) | 眼科用剤 | |
JP4473938B1 (ja) | 口腔用軟膏 | |
NZ518145A (en) | Novel hormonal composition and the use thereof | |
JP2003107416A (ja) | コンタクトレンズ用組成物及び洗眼剤組成物 | |
ES2150404T1 (es) | Composiciones farmaceuticas de tizoxanida y nitozoxanida. | |
JP2006312627A (ja) | アシタザノラスト含有組成物 | |
ES2306827T3 (es) | Composiciones de betahistina de liberacion controlada. | |
KR20010022113A (ko) | 주성분으로서 벤조피란 유도체를 함유하는 수성 액체 제약조성물 | |
AR002972A1 (es) | Pildoras que tienen una matriz farmaceutica que proporcionan un perfil apropiado de liberacion de la droga, composicion para la preparacion de dichamatriz, proceso para preparar dichas pildoras y formas de dosificacion de dicha composicion. | |
BR9909121A (pt) | Composto, composição farmacêutica, e, processos para inibir a liberação de hormÈnio de luteinização (lh) em um mamìfero em necessidade de tal tratamento e para preparar um composto |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B15K | Others concerning applications: alteration of classification |
Free format text: ALTERADA DE INT.CL: A61K 31/22, A61K 9/20, A61P 3/06 Ipc: A61K 31/22 (2008.01), A61K 9/20 (2008.01) |
|
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFIRO O PRESENTE PEDIDO, UMA VEZ QUE O MESMO NAO ATENDE AOS ARTIGOS 8O E 13 DA LPI. |
|
B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
B15K | Others concerning applications: alteration of classification |
Ipc: A61K 31/22 (2006.01), A61K 9/20 (2006.01) |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08H | Application fees: decision cancelled [chapter 8.8 patent gazette] |